Speakers
 

Josh Adler is a principal within IQVIA’s Market Access Strategy Consulting practice with over eight years of experience making evidence-based strategic recommendations with patient longitudinal analysis. He has particular expertise in biosimilars and specialty biopharma, stakeholder...

Walaa Alshafie was trained by Drs. Thomas Stroh and Peter McPherson at the Montreal Neurological Institute (McGill University). During PhD, Walaa utilized super resolution fluorescence-based imaging and identified a novel class of storage vesicles in the endocytic-recycling pathway of the...

Philip M. Arlen, M.D., President and Chief Executive Officer: Dr. Arlen spent 11 years at the National Cancer Institute, USA, most recently as the Director of the Clinical Research Group for the Laboratory of Tumor Immunology and Oncology. At the NCI, Dr. Arlen focused on the development of a...

Dr. Sameer Awsare is an Associate Executive Director for The Permanente Medical Group in charge of Pharmacy, Adult and Family Medicine, Mental Health, Risk Adjusted Coding, Revenue Cycle, Outside Medical Services, Pain Management and the Opioid Initiative.Dr. Awsare joined the Permanente Medical...

Julio's 40 year experience in the bioprocessing industry allows him to match bioprocesses with products considering technology, quality, cost and volume. Julio worked for large (Cipla, US Department of Energy, Searle, Monsanto, Upjohn) and small biotechnology companies (Fibrogen, Richmond...

Caroline is CEO and co-founder of Elasmogen, a company that discovers and develops soloMER biologics for the treatment of inflammatory diseases and cancer. Before establishing Elasmogen, she successfully led teams at Wyeth and subsequently Pfizer in Global Bio-therapeutic Technologies progressing...

Amrik has a PhD in biochemistry/protein engineering from the University of Leicester after which he spent 6 years at the Institute of Biotechnology, Cambridge University investigating bacterial pathways involved with the metabolism of illicit drugs and high explosives. In 2002, Amrik joined...

Stephen Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, School of Cancer Sciences, University of SouthamptonStephen Beers is Professor of Immunology and Immunotherapy at the Centre for Cancer Immunology, University of Southampton. He leads a research group...

As Director of Biosimilar Commercialization at AmerisourceBergen, Brian Biehn focuses on successfully executing commercialization opportunities for AmerisourceBergen while providing customers with choice, access, and savings. His role has a strong emphasis on data analytics while promoting margin...

Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018, first as senior scientist and is currently heading the Protein Engineering Group. Her main focus at Apogenix lies in the...

I obtained my Ph.D. in the field of antibody structural biology from the University of Victoria (2005-2010). My postdoctoral work was carried out at the University of Alberta (2010-2013) in the field of membrane protein structural biology.I have been a faculty member at Fresno State since 2013. My...

Craig Burton is Vice President of Policy for the Association for Accessible Medicines where he leads policy development. With nearly 20 years of Federal health policy experience, Craig has served in key roles at the center of a range of pressing health care debates. Prior to joining AAM, Craig was ...

Dr. Huan Cai is a senior scientist in analytical science and development team in CMC biologics at Teva pharmaceuticals North America. She is a passionate, highly knowledgeable and result-driven scientist with hands-on experience in cellular/molecular biology, pharmacology and analytical/biochemical ...

Ms. Ping Cao, Vice President of Business Development of Shanghai Henlius Biotech ( Henlius).  Prior to Henlius, Ms. Cao worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate...

Alex Chan is a 3rd year PhD student at University of Pennsylvania in the Bioengineering department. A member of the Tsourkas lab, he works at the intersection of protein engineering and nanoparticles to deliver inhibitors of "undruggable" proto-oncogenes. Alex is funded by the National...

Melody Chang, RPh, BCOP, MBA, is the Director of Pharmacy Operations of Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, with over 230 physicians, 200 nurse practitioners and physician assistants and nearly ...

AfPA is led by founding member David Charles, M.D., Professor and Vice-Chair of Neurology at Vanderbilt University Medical Center. He is a national leader in Movement Disorders research. Dr. Charles took leave from his practice in 1998 and spent a year on the staff of U.S. Senator Bill Frist, where ...

Dr. Qiang “Shawn” Chen is a molecular biologist who specializes in developing novel human therapeutics and vaccines in plants to combat infectious diseases, cancer, and biological warfare reagents. His research aims to ameliorate diseases and improve human health, as well as to contribute new...

Sidi Chen joined the Yale Faculty in 2015 as an assistant professor in the Department of Genetics and Systems Biology Institute, also as a member of the Yale Cancer Center and the Yale Stem Cell Center. Chen earned a PhD in evolutionary genetics from The University of Chicago with an award-winning...

Dr. Sharon Chinthrajah is an Associate Professor at Stanford University. She directs the CTRU of the Sean N Parker Center for Allergy and Asthma Research where she conducts translational research investigating immune mechanisms in food allergy and asthma. Dr. Chinthrajah completed her MD from...

Hyelim Cho, Ph.D. Immunogenicity Lead, Global DMPK Oncology & Rare Diseases, Takeda. Hyelim is a viral immunologist by training and currently works as a Immunogenicity lead in the global DMPK at Takeda Pharmaceuticals. Her group is developing methods for pre-clinical immunogenicity risk...

Mark Cragg’s research concerns how therapeutics result in tumour regression with a focus on antibodies and small molecules. The aim is to understand how these therapeutics delete tumour cells, how resistance occurs and how it might be overcome. Throughout the strategy undertaken is highly...

His laboratory has a broad portfolio of work in the area of viral immunology and antibody sciences, with the goal to discover mechanisms of immunity important to developing new therapeutics and vaccines. Dr. Crowe received his MD degree from the University of North Carolina at Chapel Hill, where...

Marc Damelin is Vice President and Head of Biology at Mersana Therapeutics, where he is focused on ADC discovery and development for oncology. Prior, he spent 10 years at Pfizer, where he led ADC discovery teams, oversaw the ADC portfolio, and mentored two postdoctoral fellows. He is the Editor of...

Dr. Davis has over 18 years of experience in industry, focused on protein and antibody engineering, bispecific and multispecific antibody platform development, and drug discovery in a wide range of therapeutic areas. Prior to joining Invenra, Dr. Davis was a Principal Scientist at Bristol-Myers...

Tim de Gavre serves as Vice President, Chief Commercial Officer at Sandoz Inc. where he is also a member of the Sandoz US Executive Committee. In his role, Tim is responsible for leading the commercial strategy and managing the market, market access, product launch, patient hub and support services ...

Dr. Brandon DeKosky is an Assistant Professor at the University of Kansas Departments of Pharmaceutical Chemistry and Chemical Engineering, where his laboratory leverages recent advances in next-generation DNA sequencing technologies to achieve a more comprehensive understanding of immune function...

John has a new unique role in Amgen Research, being responsible technology and innovation prospecting while developing, growing, and encouraging collaborations across the spectrum of Research disciplines.

Pieter Deschaght is Project Head in the Large Molecule Research Innovation team. He holds a PhD in biomedical sciences obtained at the University of Ghent (Belgium). After his PhD, Pieter joined Ablynx as a scientist with the focus on molecular engineering. In this role he contributed to the...

Iulia Diaconu PhD, is Vice President of Immunotherapy & Preclinical development at Elevate Bio and joined the company in April 2019. She is responsible for leading Elevate’s translational immunotherapy programs and developing second generation product candidates. Iulia comes from Bluebird Bio...

Dr. Yanhuai (Richard) Ding is a Director at AnaptysBio responsible for Downstream Process Development and Manufacturing Operations including clinical supply and commercial launch. He had over 19 years’ experience for protein purification, process development, technology transfer, manufacturing...

Sally joined Genentech as a Research Scientist in 2000. She moved to Development Sciences department in 2003 and is currently a Senior Director & Senior Principal Scientist in the Assay Development and Technology (ADT) group within the Bioanalytical Sciences (BAS) department. Through the past...

Agnete B. Fredriksen is Co-Founder, Chief Innovation & Strategy Officer of Vaccibody AS. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody...

Upon finishing his studies in Pharmaceutical Sciences, Norbert pursued his interdisciplinary PhD thesis in Computational Life Sciences and Pharmaceutical Chemistry at the University of Bonn focusing on computer-aided design, synthesis, and biological evaluation of protease inhibitors. After...

Dr. Rémy Gébleux (Senior Scientist, NBE-Therapeutics AG) has over 8 years of experience in the field of ADCs.He obtained his diploma degree in Chemistry from the Chemistry school of Montpellier followed by a PhD in Pharmaceutical Sciences in the Group of Pr. Dario Neri from ETH Zurich with the...

Raja Ghosh is Professor of Chemical Engineering at McMaster University, Canada. His research interests include purification of biopharmaceuticals using membrane technology and chromatography, water analysis and treatment, and membrane bioreactors for biopharmaceutical production. He has authored...

Elizabeth Hewitt Gibson joined the California Life Sciences Association (CLSA) in September 2016. As the Senior Director of Operations, she oversees CLSA’s Programs, Marketing and Human Resources functions. From CLSA’s San Diego office, she directs all aspects of program creation and statewide...

Sanjeev Gupta has done Ph.D. in Microbial biotechnology (Cell Line engineering) and M.Sc. in Applied Microbiology and Biotechnology. At present working as General Manager and Head, Advanced Biotech Lab (Biosimilar), Ipca Laboratories Ltd., Mumbai, India, and has established a new state of the art...

Eric is co-founder of four biotechnology called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy. Eric worked for 12 years in the Healthcare and Life Sciences Practice of...

Brenda Hann is the Director of Clinical Research Operations in the Stanford Cancer Clinical Trials Office at Stanford Cancer Institute.  The Cancer Clinical Trials Office provides central coordination and oversight of clinical staff to ensure consistent processes, regulatory compliance and improved ...

As Director of Pharmacy, Matt works to monitor, evaluate, and improve the pharmacy plan performance of the Employers Health $1 billion PBM group purchasing programs with CVS Health, OptumRx and EnvisionRx. He works proactively with the organization’s more than 250 member employers to provide...

Kevin Henry is a research officer at the National Research Council Canada and an adjunct professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. Prior to joining NRC in 2014, Dr. Henry completed his BSc and PhD degrees in molecular biology and...

Yue Huang received her Ph.D. from University of Washington. After joining AstraZeneca in 2016, she focused on supporting various projects with LCMS-based techniques. The LCMS bioanalytical techniques have been applied to support various project from preclinical to early clinical stage, ranging from ...

More than 20 years of experience in immunology and oncology research and drug discoveryDr. Huang initiated and developed the Immunotherapy pipeline as the Vice President of drug discovery in ACEA therapeutics. In Feb 2020, he led the spinning-off of the division from ACEA and co-founded Cytimm...

Anna Hyde is the Vice President of Advocacy and Access at the Arthritis Foundation. She oversees both the federal and state legislative programs, in addition to grassroots engagement. Her focus is to raise the visibility of arthritis as a public health priority, build support for federal and state...

Sarah Ikenberry is a Senior Communication Advisor for the Office of Therapeutic Biologics and Biosimilars (OTBB) in the Food and Drug Administration’s (FDA) Center for Evaluation and Research (CDER) where she provides communication advice and support to senior leaders and the agency about...

Tim Jacobs is the Director of Molecular Design and Engineering at AbCellera, a company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Tim joined AbCellera in 2020 following the acquisition of the...

Qualified in medicine at Karolinska Institute, Stockholm, Sweden with  30 years in various pharmaceutical and biotech R&D functions including clinical research, pharmacovigilance, regulatory, strategic product development and general management. Held roles at national, European and global level ...

Karin Jooss, Ph.D., is the head of research and development. She had most recently served as the executive vice president of research and chief scientific officer at Gritstone since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss was the head of cancer immuno-therapeutics in...

Dr Rahul Rajan Kaushik is currently at FibroGen, Inc. where he is Vice President and Head of Antibody/Protein process development and manufacturing. Prior to this he was the Executive Director and Head of external manufacturing at Nektar Therapeutics where he led CMC aspects including technology...

Kevin Knopf MD, MPH is Division Chief of Hematology/Oncology at Highland Hospital, Oakland, California and a practicing Hematologist/Oncologist. He is also a health economist and health services researcher whose research focuses on cost-effectiveness, patterns and quality of care in oncology, and...

I am a junior faculty in the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children’s Research Hospital. My research program’s goal is to develop an effective cell-based immunotherapy for childhood brain tumors using innovative technologies and models. I received PhD in ...

Dr. Krishnan has over 20 years of experience across CMC, technology transfer, and manufacturing sciences for U.S. and international manufacturing sites, involving both internal and partnered programs. As Senior Vice President of CMC and Manufacturing at Oncternal Therapeutics, he leads the process...

Vinodh Kurella is a computational biochemist with focus on biologic design and optimization. Currently, he is a director of antibody discovery group at Catabasis. Prior to which he held various positions at biotech firms, Voyager, Merrimack and Intrexon. Before completing post-doctoral training at...

Steven Lehrer brings over 30 years of experience starting, growing and running life science-based businesses focused on commercializing new technology and expanding businesses globally. Steve has extensive experience in pharmaceutical, biopharmaceutical and biosimilar...

Mr Leicher is currently in private practice providing strategic legal advice to biotechnology companies and is a regular lecturer on biotechnology and biosimilar law. He is the Former Senior Vice President and General Counsel at Momenta Pharmaceuticals Inc., an innovator biotechnology company...

Hans-Georg Lerchen is Chief Scientific Officer at Vincerx Pharma. Before joining Vincerx, he was a Distinguished Fellow in the the Pharmaceuticals R&D organization of Bayer AG. With a 33-year background in MedChem he is author or co-author of 81 patents or patent applications and 26...

Dr. Lewis is an Associate Professor of Pediatrics and Bioengineering at the University of California, San Diego. During his BS (Biochemistry, Brigham Young University), PhD (Bioengineering, UC San Diego) and postdoctoral work (Genetics, Harvard Medical School), he developed novel approaches for...

Shaun is Senior Director of Protein Engineering at Atreca, Inc, where his responsibilities include antibody lead optimization, development of multispecific therapeutics, and elucidation of epitopes of Atreca’s novel patient-derived antibodies. He has been engineering...

Cate Lockhart, MS, PharmD, PhD is the Executive Director for the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) where she is responsible for both the business and research programs of this large, multi-stakeholder research collaboration.Previously she was the HEOR expert...

Angelica Loskog is the CEO of Lokon Pharma and a Professor of immunotherapy at Uppsala University in Sweden. Further, she is a scientific advisor to the venture capital company Nexttobe AB and is a board member of several of their portfolio companies. Dr Loskog did her postdoc at Baylor College of ...

Wei Liu Ph.D. is a Director of Biological Drug Product Development in Teva Pharmaceutics.  He is responsible for biological drug product, process scale up, and tech transfer to commercial sites for process validation and commercial manufactures.   He received his Ph.D. degree from School of...

Dr. Lum is a Professor of Oncology at the University of Virginia School of Medicine, Director of Cellular Therapy, and Scientific Director of BMT. In the past 20 years, he conducted the first experimental trials using immunotherapy in combination with SCT for leukemia, lymphoma, multiple...

Athanasios (Sakis) Mantalaris is Professor in the W.H. Coulter Department of Biomedical Engineering at Georgia Tech & Emory since August 2018. Prior to his move to Atlanta, he was Professor of BioSystems Engineering in the Department of Chemical Engineering at Imperial College London. He...

As Head of Discovery at Light Chain Bioscience, Krzysztof is in charge of bispecific antibody pipeline. Krzysztof holds a Ph.D. from the University of Lausanne.

As a Product Marketing Manager at Benchling, Sean McGee has devoted his career to making therapeutics, foods, and materials safer, more effective, more sustainable, and more accessible. Prior to joining Benchling, Sean explored how machine learning and molecular modeling could accelerate...

As the Senior Director of Biosimilars, Sean McGowan is responsible for leading strategy and business development initiatives for the Biosimilar product category at AmerisourceBergen. As the Biosimilar market continues to expand, Sean partners with Biosimilar manufacturers in the...

Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing ...

Liviu Movileanu has received his Ph.D. degree in biophysics from the University of Bucharest (1997). He has acquired postdoctoral positions at the University of Missouri (Kansas City, Missouri, 1997-1998) and the Texas A&M University Health Science Center (College Station, Texas, 1999-2004). He ...

Dr. Supratik Mukhopadhyay is a faculty member in Computer Science at Louisiana State University.  He led the DeepDrug Team to the Semifinals of the IBM Watson AI XPRIZE. Currently, a combination therapy discovered by the DeepDrug AI platform that he invented is undergoing human trials at the...

Dario Neri was born in Rome on 1. May 1963 and grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry from the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich. After a post-​doctoral...

Professor Sarfaraz K. Niazi, Ph.D., FRSB, FPAMS, FACB, SI, Executive Chairman, Karyo Biologics and PharmSci, is a globally recognized pioneer of the pharmaceutical and biopharmaceutical industry, with 50+ books, 100+ research papers, 100+ patents, several approved CPs to FDA, dozens of crafted...

Previously Head of Clinical Development for Oncology at bluebird bioNine years at Pfizer Pharmaceuticals as Senior Medical Director and nearly seven years as Vice President of Global Medical Affairs at Takeda OncologyM.D. from the Carol Davila University of Medicine and Pharmacy; master’s degree in ...

Kathy Oubre is the Chief Executive Officer for Pontchartrain Cancer Center with 2 sites in southeast Louisiana.  She is the President of Louisiana Medical Group Managers Association and immediate past president of the Coalition of Hematology and Oncology Practices.  Kathy is also a Board member of...

Ms. Rachel Overman oversees the development of the antiviral and countermeasures for multi-drug resistance bacteria. She leads multi-functional teams and collaborates with joint service, interagency, international teams of scientists, and acquisition professionals in the...

Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. Prof. Parren obtained his PhD at the University of Amsterdam in 1992 after which he studied correlates of protection against viruses by human antibodies...

Dr. Perales-Puchalt serves as head of R&D for Geneos Therapeutics, adding his experience in Immuno-Oncology and DNA-based therapeutics. Previously he served in clinical development at Inovio Pharmaceuticals supporting the development of DNA vaccines and DNA-encoded bispecific antibodies for...

Edith A. Perez, MD is an internationally recognized translational researcher and cancer specialist, Chief Medical Officer of Bolt Therapeutics, Inc., Professor of Medicine at Mayo Clinic, and Director of the Mayo Clinic Breast Cancer Translational Genomics Program. Dr. Perez is known for her...

Joann Peters is the Vice President of Clinical Operations at Geneos Therapeutics. Joann joined Geneos after a successful 19-year career working in the Contract Research Organization (CRO) industry where she strategically supported the growth of companies and effectively led oncology focused study...

Dr. Elizabeth Pham holds a PhD in Biomedical Engineering from the University of Toronto and performed post-doctoral research at Sunnybrook Research Institute prior to joining Amgen Inc. as a Scientist in Immuno-Oncology. She currently heads a research group at Amgen focused on target discovery and...

May Poh Lai is a senior field application scientist at Creoptix with over 8 years’ experience in label-free technologies and 4 years’ experience providing customer support. Her background in biochemistry with a strong focus in NMR, BLI and GCI (Grating-coupled Interferometry) has given her an...

Nicolas Poirier, Chief Scientific Officer at OSE Immunotherapeutics, PhD in Immunotherapy and a Certificate in Global Management from INSEAD.Nicolas Poirier has about 15 years of experience in preclinical and translational development in biotechnology and partnership with pharmaceutical...

Ned Pojskic is Green Shield Canada’s Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC’s strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care...

Dr. Robert Popovian is the Chief Science Policy Officer at the Global Healthy Living Foundation, Vice-President, Health Economics and Policy for ConsenSys Health and Senior Healthy Policy Fellow at the Progressive Policy Institute. He previously served as Vice President, U.S. Government Relations...

Avery D. Posey, Jr., Ph.D. is an Assistant Professor in the Department of Systems Pharmacology and Translational Therapeutics, a member of the Parker Institute for Cancer Immunotherapy, and a Research Health Scientist at the Philadelphia Veterans Administration Medical Center. Dr. Posey completed...

Kamal Puri is the Chief Scientific Officer at OncoResponse Inc. He has over 25 years of R&D experience in immunology, oncology, and neurobiology. Kamal joined OncoResponse from Celgene, where he led efforts for immunology discovery. Prior to Celgene, he was at Gilead and contributed to the...

I am currently an Instructor at Baylor College of Medicine developing cellular therapies against cancer under the supervision of Dr. Cliona Rooney at the Center for Cell and Gene Therapy (CAGT). My research interests have focused on engineering T-cells that can be used as off-the-shelf treatments...

Dr. Ragheb has been with Eli Lilly & Co. for about 3 years. He is based in Indianapolis where he serves as the Senior Medical Fellow for Immunology in Global Patient Safety and Co-Chair of the Immunogenicity/Immunosafety Working Group.He received his MD and PhD degrees from the Johns Hopkins...

Experienced Professor with a Ph.D. in Pharmaceutical Marketing and over 21 years of academic and research experience in the field of Pharmaceutics. Innovative andmulti-disciplinary scientist with strong analytical and problem-solving skills in Data Analysis and Pharmaceutical Research. Interest in...

​​​​​​Jonah completed a PhD in Biochemistry at Tufts University and postdoc at University of Wisconsin and the Salk Institute. He has 15 years’ experience in discovery, research and development of bispecific antibodies. He authored several patents and publications describing bispecific platforms...

Susan Raiola is the President of Real Endpoints. Ms. Raiola has over 10 years of experience in the pharmaceutical consulting industry with a primary emphasis on reimbursement and market access. Ms. Raiola's experience ranges across multiple therapeutic areas including...

Dr. Ramanan is a seasoned regulatory affairs executive with a broad and deep expertise in biopharmaceutical drug development, global regulatory affairs and policy.  Prior to Biocon, he was responsible for Amgen’s International Regulatory Strategy and Policy for Biologics & Biosimilars.  He has...

Romesh has over seven years of experience in biopharmaceutical analytical development and has an in-depth knowledge of mass spectrometry techniques and protein characterization. He joined Seattle Genetics as a member of the Analytical Sciences Mass Spectrometry Core Group in 2015. In his current...

Michael Reilly, Esq., is the Executive Director of the Alliance for Safe Biologic Medicines (ASBM) who have been leading education and advocacy efforts on all issues related to biosimilars since 2010.  ASBM is an organization of patients, physicians, pharmacists and biotechnology companies working...

Anton Rosenbaum is Head of Regulated Bioanalysis and OMICS by LC-MS within Integrated Bioanalysis at AstraZeneca. His group supports a variety of preclinical and clinical programs focusing on novel therapeutic modalities across the portfolio of diverse therapeutic areas. Anton’s expertise is...

Dr. Maria Germana Sanna is currently a Field Application Scientist at Gyros Protein Technologies.She has been with the company since 2018 and prior to joining the company she was a Staff Scientist/ Senior Staff Scientist in the departments of Immunology, Chemical Physiology and Molecular Medicine...

Dr. Sauer is a Vice President at Repertoire Immune Medicines, Cambridge, MA, which uses cutting-edge technology to decode T cell clonotypes and associated antigen epitopes in autoimmune diseases and cancer. Repertoire uses the results to develop clonotype or antigen-specific immunotherapies, aiming ...

Dr. Nishant Saxena is a product manager for protein and antibody purification products in GenScript USA. He has multiple years of lab experience in protein and antibody purification with a special focus on monoclonal antibody production using hybridoma technology. In this talk, he will present an...

Emmett received his undergraduate degree in Biology from Harvard College in 1974 and a simultaneous M.A. in Biology. He received MD and PhD degrees having attended medical school and graduate school at the Duke University School of Medicine from 1975 to 1981. He completed internship, residency and...

Philip is the Chair of the International Advisory Board for the Alliance for Safe Biologic Medicines, which serves as an authoritative resource center of information for the public, as well as the healthcare and health policy communities, on the issues surrounding biologic medications.  Professor...

Dr. Janine Schuurman is a scientist at heart and an expert in antibody biology and translational research. Following her passion to develop innovative antibody therapeutics, Dr. Schuurman joined Genmab in 2000. She currently serves in the position of Senior Vice President Antibody Research &...

Executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs.C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study...

As Global Head of the Large Molecules Research Platform at Sanofi, Rebecca is responsible for the progression of the Large Molecules portfolio, which includes discovery, design and generation of novel biologics from target validation to IND-filing.  Sanofi’s innovative biologics portfolio includes...

Dr. Alessandro Sette has devoted more than 30 years to understanding and measuring immune responses, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. Dr. Sette laboratory is focused on the study of the specific structures (epitopes) that ...

Dr. Bernhard Sielaff is a Principal Research Scientist II and leads the Biologics Protein Purification Group in Global Protein Sciences at the AbbVie Bioresearch Center (ABC) in Worcester, MA. His group is responsible for the design and purification of antigens and novel therapeutic formats to...

Dr. Jamie Spangler earned a Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and went on to earn a Ph.D. in Biological Engineering at MIT. After completing a postdoctoral fellowship at Stanford University School of Medicine, Dr. Spangler launched her independent...

Denise Steckel has over 22 years of experience at Genentech in Operations Support at two Genentech sites. She managed Operations support for manufacturing, Quality Assurance for finished goods manufactured at Contract Manufacturing Sites and External Collaborations for combination...

Anish Suri is an immunologist with more than 20 years of experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical ...

Peter is a final year PhD student in the Chudasama group at University College London, working on chemically generated bispecific and multispecific antibodies and their conjugates. He has an interest in using the chemical tools their lab developed for immunotherapy and oncology, whether in the form ...

Pam Traxel serves as the Senior Vice President for ACS CAN, the advocacy affiliate of the America Cancer Society.  Pam is responsible for helping ACS CAN develop relationships with companies and individuals to help further the fight against cancer through dynamic partnerships, events, and forums. ...

I got my Bachelor’s in Chemistry and Philosophy at Creighton University in Omaha working in synthetic organic chemistry. I then went to the University of Minnesota, where I received my Ph.D. working under Will Pomerantz developing protein-observed fluorine NMR as a ligand discovery technique. Since ...

The van Gils lab is committed to make a lasting impact on the field of vaccine immunology. Our mission is to comprehend the underlying immunology behind vaccination, in particular the elicitation of antibody responses. These antibody responses are vital in the protection against infectious diseases ...

Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely...

Chris Webster is a regulatory affairs consultant specialising in biologics and vaccines and principal of BioApprovals. Before founding BioApprovals, Chris led regulatory affairs groups at different companies for over 25 years, most recently heading biosimilars at Baxalta and previously leading...

​​​​​​​Bingchuan is currently a Senior Scientist in Genentech Research and Early Development (gRED). He is leading a group providing the analytical support for various modalities of therapeutics including small molecules, oligonucleotides and proteins. Bingchuan's research focus is developing...

Dr. Wild joined Dracen Pharmaceuticals in 2017 as one of the founding executives and Chief Scientific Officer (CSO). He is responsible for all discovery, preclinical development and translational research efforts of Dracen?s therapeutic pipeline and leads scientific strategy. Dr. Wild is a seasoned ...

Farrah Wong, PharmD, is senior director of Commercial Formulary Contracting Strategy at OptumRx, one of the largest pharmacy benefit managers in the United States. Her primary responsibilities include formulary management and strategy, forecasting, and trend assessment. These initiatives drive the...

David Wood is a professor of Chemical Engineering at the Ohio State University and has been working on intein technology for close to 25 years.  He has also worked in industry at Amgen and BMS, and has developed a number of useful tools through multidomain protein engineering.

Dr. Gillian Woollett joined Samsung Bioepis in November 2021 as VP, Head Regulatory Strategy and Policy, US (SBUS), to stand up a US presence for science-based regulatory strategy and policy in the leading global market for biologics, including but not limited to biosimilars.Prior to this recent...

Dr. Wang obtained his bachelor’s and master’s degrees in Mechanics and Fluid Mechanics from Peking University, Beijing, P.R. China, in 1992 and 1996, respectively. He received his Ph.D. degree in Bioengineering from the University of California, San Diego Jacobs School of Engineering in 2002 and...

Kevin has over 20 years of broad experience in developing biologics drugs: Biologics CMC – Strategic and Technical Operations. In addition to developing therapeutic biological products in house, he also had extensive experience working with external contract manufacturing organizations (CMO) and...

Dr. Zhang Yu is the SVP&CSO of Vcanbio Cell&Gene Engineering Corp.,Ltd and CEO of Vcanpharma. Dr. Zhang was the former president and CEO of Aeon Therapeutics, a joint-venture biotech company between Eureka Therapeutics Inc. Dr. Zhang received his B.S. in Bioengineering and M.S. in...

Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. During his PhD he spent some time at Scripps Institute, La Jolla (USA) working in the lab of Vaughn...